Malignant Melanoma
Showing 1 - 25 of 7,605
EVALUATING THE CURRENT STANDARD OF CARE FOR PATIENTS DIAGNOSED
Not yet recruiting
- Melanoma (Skin)
- Melanoma
- (no location specified)
Jun 2, 2023
Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin Trial in Santiago (TAPCells vaccine)
Completed
- Stage III Malignant Melanoma of Skin AJCC V6
- Stage IV Malignant Melanoma of Skin
- TAPCells vaccine
-
Santiago, RM, ChileFaculty of Medicine, University of Chile
Nov 21, 2023
Malignant Melanoma, Angiosarcoma Trial in Chuo Ku (CICS-1 (investigational device),SPM-011(investigational drug))
Active, not recruiting
- Malignant Melanoma
- Angiosarcoma
- CICS-1 (investigational device),SPM-011(investigational drug)
-
Chuo Ku, Tokyo, JapanNational Cancer Center Hospital
Nov 6, 2022
A Storage Facility for Tissues Obtained From Malignant Melanoma
Recruiting
- Melanoma
- Biospecimen Collection
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 6, 2022
Melanoma Trial in Toronto (Definity, Sonalleve Focused Ultrasound Device)
Recruiting
- Melanoma
- Definity
- Sonalleve Focused Ultrasound Device
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Centre
Nov 16, 2022
Malignant Melanoma, Liver Metastases Trial (Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel)
Not yet recruiting
- Malignant Melanoma
- Liver Metastases
- Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
- (no location specified)
Dec 23, 2022
Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)
Enrolling by invitation
- Malignant Melanomas
- Recombinant Human Adenovirus Type 5 Injection
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023
Malignant Melanoma, Merkel Cell Carcinoma Trial in Bern (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System
Completed
- Malignant Melanoma
- Merkel Cell Carcinoma
- Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)
-
Bern, Kanton Bern, SwitzerlandInselspital, University Hospital Bern, University of Bern
Dec 7, 2022
Melanoma, Malignant Melanoma Trial (T3011 + Cobimetinib)
Not yet recruiting
- Melanoma
- Malignant Melanoma
- T3011 + Cobimetinib
- (no location specified)
Mar 3, 2023
Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)
Completed
- Unresectable Stage IIIB-IV Malignant Melanoma
- Talimogene laherparepvec
-
Nagoya-shi, Aichi, Japan
- +8 more
Jan 13, 2023
Cutaneous Malignant Melanoma Trial in Belgium, Hungary (Vitamin D, arachides oleum raffinatum)
Active, not recruiting
- Cutaneous Malignant Melanoma
- Vitamin D
- arachides oleum raffinatum
-
Edegem, Belgium
- +3 more
May 18, 2022
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin Trial in Marlborough (PH-762)
Not yet recruiting
- Squamous Cell Carcinoma of the Skin
- +2 more
-
Marlborough, MassachusettsPhio Pharmaceuticals Corp.
Aug 25, 2023
Sample Collection From Melanoma Patients
Terminated
- Melanoma
- Blood Sample
- Tumor Sample
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 31, 2022
Malignant Melanoma Trial in Los Angeles, Houston, Uppsala (delolimogene mupadenorepvec, atezolizumab)
Recruiting
- Malignant Melanoma
- delolimogene mupadenorepvec
- atezolizumab
-
Los Angeles, California
- +2 more
Apr 4, 2022
SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)
Not yet recruiting
- SCLC
- +2 more
- GD2-SADA:177Lu-DOTA Complex
- (no location specified)
May 4, 2022
Yervoy® Postmarketing Surveillance for Japan With Unresectable,
Completed
- Melanoma
-
Chiyoda-ku, Tokyo, Japan
- +1 more
Feb 11, 2022
Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)
Not yet recruiting
- Malignant Melanoma
- +4 more
- Pembrolizumab
- +2 more
- (no location specified)
Mar 31, 2022
Malignant Melanoma, Sinonasal Melanoma Trial in Shanghai (endoscopic surgery)
Recruiting
- Malignant Melanoma
- Sinonasal Melanoma
- endoscopic surgery
-
Shanghai, Shanghai, ChinaEye& ENT Hospital, Fudan University
May 8, 2022
Malignant Melanoma Trial in Herlev, Aarhus, Odense (Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab
Recruiting
- Malignant Melanoma
- Pembrolizumab Injection [Keytruda]
- +6 more
-
Herlev, Hovedstaden, Denmark
- +2 more
Sep 16, 2022
Melanoma Trial in East Melbourne, Heidelberg (NY-ESO-1 ISCOMATRIX® vaccine, Cyclophosphamide)
Completed
- Melanoma
- NY-ESO-1 ISCOMATRIX® vaccine
- Cyclophosphamide
-
East Melbourne, Victoria, Australia
- +1 more
Oct 3, 2022
Locally Advanced or Metastatic Acral Malignant Melanoma Trial in Jinan (Toripalimab and Anlotinib)
Not yet recruiting
- Locally Advanced or Metastatic Acral Malignant Melanoma
- Toripalimab and Anlotinib
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
Oct 8, 2021